Ipsen Taps Alltrna CEO Michelle Werner to Lead North America Operations

Event summary

  • Michelle C. Werner appointed EVP, President of North America at Ipsen, effective March 23, 2026.
  • Werner joins from Alltrna, where she served as President and CEO since 2022.
  • She brings 25+ years of experience in pharmaceuticals, with roles at BMS, AstraZeneca, and Novartis.
  • Keira Driansky, outgoing EVP and President for North America, led a transformation increasing U.S. sales and brand visibility.

The big picture

Ipsen's appointment of Michelle Werner underscores its commitment to strengthening its presence in the U.S. market, particularly in high-growth areas like oncology and rare diseases. This move aligns with broader industry trends of strategic hires aimed at driving market expansion and operational efficiency. With a focus on transformative medicines, Ipsen is positioning itself to capitalize on the increasing demand for specialized therapies.

What we're watching

Strategic Focus
How Werner's expertise in oncology and rare diseases will accelerate Ipsen's growth in these therapeutic areas.
Market Penetration
Whether Ipsen can sustain the momentum in U.S. sales and brand visibility under new leadership.
Leadership Transition
The pace at which Werner integrates and aligns Ipsen's North American operations with global strategies.

Related topics

Pharmaceuticals